EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[SMC Monday GI conference 2016-8-8. Barrett esophagus and colorectal neoplasia pathway]

Previous | Next

[Àü´Þ »çÇ×]

1. ÆòÀÏ ÇÐȸ³ª Áý´ãȸ Âü¼®¿¡ ´ëÇÏ¿©: ¹ßÇ¥ÀÚ ÀÌ¿Ü¿¡´Â Á¤ÇØÁø ÀÓ»ó scheduleÀ» ÁöÄÑÁֽñ⠹ٶø´Ï´Ù. Çмú¸ðÀÓÀÌ ÀÖ´Â ³¯¿¡´Â 5ºÐ ÀÏÂï ½ÃÀÛÇÑ´Ù´Â ¸¶À½°¡ÁüÀ¸·Î ¸ðµÎ Á¶±Ý¾¿ ¼­µÑ·¯ÁÖ¸é ÁÁÁö ¾ÊÀ»±î¿ä? ¿©·¯ºÐÀÌ Âü¼®ÇØ¾ß ÇÏ´Â °æ¿ì´Â »çÀü¿¡ ¾Ë·ÁÁּż­ schedule¿¡ ¹Ý¿µµÇµµ·Ï ÇØ ÁÖ¼¼¿ä.

2. ´çÁ÷ scheduleÀ» º¯°æÇÒ ¶§¿¡´Â ¼ÒÈ­±â³»°ú ºñ¼­½Ç·Î ²À ¿¬¶ôÇØ ÁÖ¼¼¿ä.

3. ÁøÁ¤³»½Ã°æ¿¡¼­ midazolamÀ» ȯÀÚ¿¡°Ô Åõ¿©Çϱâ Àü¿¡´Â ³»½Ã°æ Àǻ簡 ȯÀÚ¿Í ÇÑ ¸¶µð¶óµµ ³ª´©½Ã±â ¹Ù¶ø´Ï´Ù. ³»½Ã°æ½Ç¿¡ µé¾î¿ÀÀÚ¸¶ÀÚ ÀÇ»ç ¾ó±¼µµ º¸Áö ¸øÇÑ È¯ÀÚ¿¡¼­ midazolamÀ» Åõ¿©ÇÏ´Â °ÍÀº ¿¹ÀÇ°¡ ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù.


1. ÀÓ»ó°­»ç ¾ÈÁؼº ¼±»ý´Ô²²¼­´Â ¹Ù·¿½Äµµ ³»½Ã°æÁø´Ü (´ëÇѼÒÈ­±â³»½Ã°æÇÐȸÁö 2009)°ú ACG guideline (AJG 2016)À» Áß½ÉÀ¸·Î ¹ßÇ¥ÇØ Áּ̽À´Ï´Ù.

ABSTRACT: Barrett's esophagus (BE) is among the most common conditions encountered by the gastroenterologist. In this document, the American College of Gastroenterology updates its guidance for the best practices in caring for these patients. These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors. Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3-5 years. Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time. Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma. Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative. Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals. Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE. (ACG guideline (AJG 2016))

1 cm ¹Ì¸¸ÀÇ ultra-short segment Barrett esophagus´Â ÃÖ±Ù °­Á¶µÇÁö ¾Ê´Â ºÐÀ§±âÀÔ´Ï´Ù. Àú´Â Àü°øÀÇ, fellow µé²² 1cm ¹Ì¸¸Àº ¹«½ÃÇϵµ·Ï ±ÇÇÏ°í ÀÖ½À´Ï´Ù.

Áý´ãȸ¿¡¼­ ³íÀÇÇÏ¿´´Âµ¥ ³»¿ë¿¡ ´ëÇÏ¿© ´ëºÎºÐ Âü¼®ÀÚ°¡ µ¿ÀÇÇÏ¿´½À´Ï´Ù. ´Ù¸¸ '1-2³â ÈÄ ÃßÀû³»½Ã°æ °Ë»ç¸¦ ÃßõÇÑ´Ù' ºÎºÐÀ» '1³â ÈÄ'·Î ¹Ù²Ù¸é ÁÁ°Ú´Ù´Â ÀÇ°ßÀÌ ÀÖ¾ú½À´Ï´Ù.

¹Ù·¿½Äµµ ¿µ¿ª¿¡¼­ ÃÖ±Ù °¡Àå ´Þ¶óÁø Á¡ÀÔ´Ï´Ù. PPI°¡ µµ¿òÀÌ µÉ °ÍÀ̶ó´Â Áõ°Å°¡ ÃàÀûµÇ°í ÀÖ½À´Ï´Ù.

2016³â ACG guideline¿¡ óÀ½À¸·Î PPI »ç¿ëÀÌ ¾ð±ÞµÇ¾ú½À´Ï´Ù. ±¹³»¿¡¼­´Â ¾ÆÁ÷ º¸Çè±Þ¿©´Â µÇÁö ¾Ê°í ÀÖ½À´Ï´Ù. ¾à°£ÀÇ »ê¿ª·ù Áõ»óÀ» °¡Áø ºÐµéÀÌ ¸¹À¸¹Ç·Î Àû¾îµµ À̵鿡°Ô´Â PPI¸¦ Åõ¿©ÇÏ°í ÀÖ½À´Ï´Ù.

ÀåºÐÀý ¹Ù·¿½ÄµµÀÔ´Ï´Ù. Áß°£ Áß°£¿¡ squamous island°¡ º¸ÀÔ´Ï´Ù. Hiatal hernia°¡ µ¿¹ÝµÇ¾î ÀÖ½À´Ï´Ù. ÀåºÐÀý ¹Ù·¿½Äµµ¿¡¼­ hiatal hernia°¡ ¾ø´Â °æ¿ì°¡ °ÅÀÇ ¾ø½À´Ï´Ù.

´ÜºÐÀý ¹Ù·¿½ÄµµÀÌ°í hiatal hernia°¡ µ¿¹ÝµÇ¾î ÀÖ½À´Ï´Ù. 1½Ã, 3½Ã ¹æÇâÀ» Á¦¿ÜÇϸé Àü¹ÝÀûÀ¸·Î circumferential ÇÑ ´ÜºÐÀý ¹Ù·¿½ÄµµÀÔ´Ï´Ù. Palisading vesselÀÌ Àß º¸ÀÌ°í Àֳ׿ä.

¿ª·ù¼º ½Äµµ¿°ÀÌ µ¿¹ÝµÈ °æ¿ìÀÔ´Ï´Ù. »ç½Ç ¹Ù·¿½Äµµ¿¡ ¿ª·ù¼º ½Äµµ¿°ÀÌ µ¿¹ÝµÈ ¿¹´Â ¸¹Áö ¾Ê½À´Ï´Ù. Á¦ ªÀº °æÇèÀ¸·Î º¸¸é ¿ª·ù¼º ½Äµµ¿°ÀÌ µ¿¹ÝµÈ °æ¿ì´Â ¹Ù·¿½Äµµ ±æÀÌ°¡ ±æ¾îÁö´Â °Í °°½À´Ï´Ù. ¿ª·ù¼º ½Äµµ¿°ÀÌ ¾ø´Â °æ¿ì´Â ¹Ù·¿½Äµµ°¡ ±æ¾îÁö´Â °æ¿ì°¡ °ÅÀÇ ¾ø½À´Ï´Ù.

* Âü°í: EndoTODAY ¹Ù·¿ ½Äµµ


2. ±è¼ø¿µ ¼±»ý´Ô²²¼­´Â Colorectal neoplasia pathways (Gastrointest Endosc Clin N Am 2015)¸¦ Áß½ÉÀ¸·Î ¹ßÇ¥Çϼ̽À´Ï´Ù.

A, SSP rim of debris (solid arrows) obscuring the course of a submucosal vein (dashed arrow)
B, SSP mucous cap (arrow)
C, SSP rim of debris/bubbles, obscuring an underlying vessel (arrow),
D, Lesion in C seen under NBI. abrupt cutoff of the submucosal vein (arrow), typical reddish appearance of the mucous cap.
E, SSP debris-stained mucous cap
F, Flat SSP the lesion (solid arrow) has been lifted by submucosal saline solution injection. , a nonlifted portion of the lesion (dashed arrow)
G, Protuberant SSP displaying a dome shape and mucous cap
H, SSP dome shape, mucous cap, and altering the contour of a mucosal fold
I, SSP draped over a mucosal fold (solid arrow)
J, SSP red coloration relative to the background mucosa. A subtle rim of debris Lesion obscures underlying submucosal vessels
K, Flat SSP subtle nodular appearance of surfacemucosa. The solid arrows indicate the extent of the lesion
L, The same lesion as in K, seen under NBI and from a closer distance. Intracolonic air has been aspirated, eliciting more conspicuous nodularity.

* Âü°í: EndoTODAY Serrated adenoma

© EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà